Neuroscience heavyweight Neurocrine Biosciences is officially expanding its footprint. In a massive move into the metabolic disorder space, the company has agreed to acquire rare-disease drugmaker Soleno Therapeutics for $2.9 billion in cash.
💰 THE DEAL METRICS:
- The Price Tag: An all-cash $2.9 billion buyout, priced at $53 per share (representing a 34% premium to Soleno’s last close). Soleno shares immediately surged ~33% on the news.
- The Funding: The deal will be funded primarily with cash on hand, plus a modest amount of prepayable debt, with an expected close in the next 90 days.
- The Portfolio Fit: Neurocrine’s existing rare-disease drugs (Ingrezza and Crenessity) already generated $2.81 billion in 2025. This acquisition adds a highly lucrative “third leg” to their revenue stool.
🧬 THE CROWN JEWEL (Vykat XR):
- The Catalyst: The acquisition gives Neurocrine full control of Vykat XR, the very first U.S.-approved drug to treat hyperphagia (intense, persistent hunger) associated with Prader-Willi syndrome.
- The Blockbuster Potential: The drug is already a massive success, pulling in $190 million in 2025 just nine months post-approval. Wall Street analysts project Vykat XR will cross the $1 billion annual sales threshold by 2029.
- The Strategy: While it operates in the obesity-adjacent space, the drug specifically targets the neurological triggers of hyperphagia. Neurocrine’s CEO noted that intervening early in younger patients can help maintain weight over time, though the immediate rollout will remain strictly focused on the U.S. market.
💡 THE BOTTOM LINE: Biotech M&A is getting highly strategic. Neurocrine isn’t just buying a drug; they are buying a bridge. By acquiring the premier treatment for a neurologically-driven metabolic disorder, Neurocrine is perfectly leveraging its historical neuroscience expertise to tap into the massively profitable metabolic and weight-management sector.